Free Trial
→ I was wrong. Dead wrong. (From Porter & Company) (Ad)

The 12 Most-Hated Stocks on Wall Street - 12 of 12

Slide 12
Back to 11
Next Slideshow
 
Back to 11
Next Slideshow
 

BioMarin Pharmaceutical (NASDAQ:BMRN)

Number of Downgrades
17 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
16 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$94.20 (44.0% Upside)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/15/2024Wolfe ResearchInitiated CoverageOutperform$95.00
11/4/2024WedbushUpgradeStrong-Buy
10/30/2024CitigroupLower Price TargetNeutral ➝ Neutral$93.00 ➝ $81.00
10/30/2024Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$110.00 ➝ $90.00
10/30/2024Canaccord Genuity GroupLower Price TargetHold ➝ Hold$93.00 ➝ $84.00
10/30/2024JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$110.00 ➝ $109.00
10/30/2024Evercore ISILower Price TargetOutperform ➝ Outperform$115.00 ➝ $105.00
10/30/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$80.00 ➝ $80.00
10/30/2024UBS GroupBoost Price TargetBuy ➝ Buy$104.00 ➝ $106.00
10/30/2024Robert W. BairdLower Price TargetNeutral ➝ Neutral$72.00 ➝ $65.00

More Investing Slideshows:

Slide 12
Back to 11
Next Slideshow
 

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

More From MarketBeat
Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...
Brownstone Research | Sponsored
7 Best Growth Stocks for the Next 10 Years
If you're somewhat new to investing, the term “growth stocks" may be confusing. After all, don't you wan...
MarketBeat
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...
Crypto Swap Profits | Sponsored
7 Restaurant Stocks to Profit from the Trend Towards Fast Casual
If you're a data-driven investor, you may be surprised to learn that fast-casual restaurant stocks are some of...
MarketBeat
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...
Timothy Sykes | Sponsored
8 Retail Stocks to Own For the Long Haul
After the 2020 e-commerce boom, everyone thought we had taken a 10-year leap in online shopping. Amazon was op...
MarketBeat